✦ LIBER ✦

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

✍ Scribed by J. Huober; P.A. Fasching; M. Barsoum; L. Petruzelka; D. Wallwiener; C. Thomssen; T. Reimer; S. Paepke; H.A. Azim; V. Ragosch; E. Kubista; A.K. Baumgärtner; M.W. Beckmann; C. May; I. Nimmrich; N. Harbeck

Book ID: 113507385
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 350 KB
Volume: 21
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2011.07.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN97 A COST-UTILITY ANALYSIS ON THE USE

PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB + ANASTROZOLE COMPARED TO LAPATINIB + LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

✍ S McNamara; L Moore; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

2108 POSTER Cardiac safety of trastuzuma

2108 POSTER Cardiac safety of trastuzumab in combination with epirubicin/ cyclophosphamide as first-line therapy in patients with HER2-positive metastatic breast cancer

✍ M. Untch; S. Tjulandin; W. Jonat; H. Meerpohl; M. Lichinitser; G.M. Manikhas; F. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Randomized phase III trial of trastuzuma

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

446 PUBLICATION A phase II trial of tras

446 PUBLICATION A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER-2-positive metastatic breast cancer (MBC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

A cost-effectiveness analysis of Hercept

A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK

✍ A. Ratcliffe; C. Poole; D. Miles 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 165 KB

2124 POSTER Triple combination of oral v

2124 POSTER Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial

✍ A. Chan; V. Ganju; D. Becquart; P.F. Conte; L. Petruzelka; O. Perrot; G. Villano 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 78 KB